Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROGRESS phase 2 trial of zilurgisertib in fibrodysplasia ossificans progressiva
CTR20230239Phase 2Active
- Sponsor
- Incyte
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zilurgisertib in fibrodysplasia ossificans progressiva (FOP), sponsored by Incyte. Started Apr 2023; status: active.
02
Drugs
zilurgisertib
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on CTR20230239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230239.